Skip to main content

Table 1 Baseline characteristics: COPD subjects included in the longitudinal follow-up data, stratified by medication groups

From: Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort

 

All COPD subjects

Chronic oral steroids

TIO/LABA/ICS

TIO

ICS ± LABA

SAB

N =

3828

174

863

256

628

366

Gender (female)

2091 (52 %)

87 (50 %)

447 (52 %)

120 (47 %)

305 (49 %)

218 (60 %)

Race (African-American)

736 (19 %)

50 (29 %)

155 (18 %)

35 (14 %)

112 (18 %)

92 (25 %)

Oxygen Therapy

948 (36 %)

87 (50 %)

455 (53 %)

71 (28 %)

165 (26 %)

57 (16 %)

Chronic Bronchitis

968 (30 %)

52 (30 %)

242 (28 %)

65 (25 %)

186 (30 %)

128 (35 %)

Doctor's Diagnosis of Asthma

918 (32 %)

71 (41 %)

271 (31 %)

41 (16 %)

247 (39 %)

107 (29 %)

Frequent Cough Symptom

1597 (47 %)

87 (50 %)

369 (43 %)

118 (46 %)

289 (46 %)

204 (56 %)

Frequent Phlegm Symptom

1739 (52 %)

107 (61 %)

420 (49 %)

115 (45 %)

328 (52 %)

209 (57 %)

Hay Fever

1156 (33 %)

69 (40 %)

263 (30 %)

79 (31 %)

235 (37 %)

113 (31 %)

GERD

1142 (34 %)

54 (31 %)

313 (36 %)

85 (33 %)

220 (35 %)

114 (31 %)

Cardiovascular Disease

748 (22 %)

31 (18 %)

197 (23 %)

63 (25 %)

129 (21 %)

83 (23 %)

Age (years)

63.8 ± 8.3

63.7 ± 8.6

64.5 ± 7.7

66.3 ± 8.1

64.6 ± 8.5

62.5 ± 8.6

Pack Years of Smoking

51.7 ± 28

51.5 ± 29

54.1 ± 26

53.5 ± 28

52.8 ± 30

54.3 ± 29

Current Smoking

1486 (39 %)

42 (24 %)

188 (22 %)

88 (34 %)

202 (32 %)

202 (55 %)

6MWT distance (ft)

1250 ± 380

943 ± 400

1068 ± 350

1216 ± 320

1206 ± 390

1212 ± 370

FEV1 percent predicted

57.2 ± 20

39.3 ± 19

41.7 ± 17

54.4 ± 19

53.1 ± 20

56.1 ± 19

FEV1/FVC

0.52 ± 0.13

0.43 ± 0.12

0.43 ± 0.12

0.49 ± 0.11

0.50 ± 0.13

0.53 ± 0.12

GOLD 1

660 (17 %)

6 (3 %)

21 (2 %)

23 (9 %)

60 (10 %)

44 (12 %)

GOLD 2

1634 (43 %)

37 (21 %)

238 (28 %)

120 (47 %)

275 (44 %)

174 (47 %)

GOLD 3

1022 (27 %)

67 (39 %)

364 (42 %)

84 (33 %)

209 (33 %)

116 (32 %)

GOLD 4

512 (13 %)

64 (37 %)

240 (28 %)

29 (11 %)

84 (13 %)

32 (9 %)

MMRC Score

1.9 ± 1.3

3.0 ± 1.1

2.8 ± 1.1

2.0 ± 1.2

2.3 ± 1.3

2.0 ± 1.4

SGRQ Total Score

36.2 ± 19

57.2 ± 17

49.1 ± 18

38.9 ± 17

42.6 ± 20

41.9 ± 20

BODE score

2.5 ± 1.9

4.4 ± 1.9

4.0 ± 1.7

2.6 ± 1.7

2.9 ± 1.9

2.6 ± 1.8

TLC by CT percent predicted

102.3 ± 17

104.5 ± 17

106.1 ± 18

101.9 ± 15

104.3 ± 17

100.4 ± 16

SRWA-Pi10

3.70 ± 0.14

3.76 ± 0.13

3.72 ± 0.14

3.70 ± 0.14

3.73 ± 0.15

3.74 ± 0.16

Percent Emphysema

12.0 ± 13

18.4 ± 14

19.5 ± 14

12.7 ± 10

12.7 ± 12

8.8 ± 9.4

Percent Gas Trapping

36.4 ± 20

47.7 ± 20

48.7 ± 19

39.0 ± 17

39.3 ± 20

33.8 ± 20

BMI (kg/m^2)

28.0 ± 6.4

27.9 ± 6.3

27.8 ± 6.3

27.8 ± 6.1

28.4 ± 6.5

28.8 ± 7.1

Exacerbations/Year in Follow-Up

0.7 ± 1.4

1.5 ± 2.0

1.1 ± 1.7

0.5 ± 0.9

0.7 ± 1.1

0.6 ± 1.1

Severe Exacerbations/Year

0.2 ± 0.8

0.6 ± 1.3

0.4 ± 0.9

0.1 ± 0.3

0.2 ± 0.6

0.2 ± 0.6

  1. Mean (SD) or N (%) are shown. See Methods for group definitions. N (%) or Mean ± SD are shown
  2. TIO Tiotropium, ICS ± LABA long-acting beta-agonist/inhaled corticosteroid, SAB short-acting bronchodilator, 6MWT six minute walk test distance, TLC total lung capacity, CT computed tomography, FEV forced; expiratory volume in one second, GERD gastroesophageal reflux disease, SRWA-Pi10 square root wall; area of a 10 mm airway, BMI body mass index
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us